DDInter582 DDInter278
Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013. On November 21, 2017, dolutegravir, in combination with rilpivirine, was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca.
Calcium lactate is a salt that consists of two lactate anions for each calcium cation (Ca2+). It is prepared commercially by the neutralization of lactic acid with calcium carbonate or calcium hydroxide. Approved by the FDA as a direct food substance affirmed as generally recognized as safe, calcium lactate is used as a firming agent, flavoring agent, leavening agent, stabilizer, and thickener . Calcium lactate is also found in daily dietary supplements as a source of calcium. It is also available in various hydrate forms, where calcium lactate pentahydrate is the most common.
Dolutegravir {u} (Compound) binds {v} (Gene) UGT1A1
Dolutegravir {u} (Compound) is included by {v} (Pharmacologic Class) Organic Cation Transporter 2 Inhibitors
Dolutegravir {u} (Compound) causes {v} (Side Effect) Rash generalised
Dolutegravir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Griseofulvin
Dolutegravir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Somatrem
Dolutegravir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofarabine
Dolutegravir {u} may lead to a major life threatening interaction when taken with {v} Tetraferric tricitrate decahydrate
Dolutegravir {u} may lead to a major life threatening interaction when taken with {v} Iron
Dolutegravir (Compound) binds UGT1A1 (Gene)
Dolutegravir (Compound) is included by Organic Cation Transporter 2 Inhibitors (Pharmacologic Class)
Dolutegravir (Compound) causes Rash generalised (Side Effect)
Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Griseofulvin
Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Somatrem
Dolutegravir may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Dolutegravir may lead to a major life threatening interaction when taken with Tetraferric tricitrate decahydrate
Dolutegravir may lead to a major life threatening interaction when taken with Iron